Godinho J, Casa-Nova M, Moreira-Pinto J, et al. - Given a higher risk of venous thromboembolism (VTE) in patients with pancreatic cancer, which is commonly related to treatment delays or interruptions, researchers focused on the incidence of VTE as well as on the performance of ONKOTEV score as a tool for predicting VTE in a population of patients with pancreatic cancer studied in this retrospective study. This study was done with 165 patients, with median age of 73 years, 45.5% were female, stage IV disease was present in 55.8%. A VTE was detected in 51 patients (30.9%); pulmonary embolism, deep venous thrombosis, and visceral VTE was present in 23.5%, 25.5%, and 51.0%, respectively. Participants were observed for a median duration of 6.3 months, at which, the cumulative incidence of VTE was estimated to be less than 10% for ONKOTEV scores 0 or 1 and about 40% and 70% for scores 2 and ≥ 3, respectively. In line with previous reports, a high incidence of VTE was reported. Experts recommended considering primary thromboprophylaxis for patients at high risk for VTE with no increase in hemorrhagic risk. Stratification of patients with pancreatic cancer based on VTE risk may be enabled by the ONKOTEV score, with ONKOTEV score ≥ 2 being related to a higher VTE occurrence.